SlimQuick™- associated hepatotoxicity in a woman with alpha-1 antitrypsin heterozygosity

World Journal of Hepatology

Volumn 4, Issue 4, 2012, Pages 154-157

  Weinstein, Douglas H ^a   Twaddell, William S ^a   Raufman, Jean Pierre ^a   Philosophe, Benjamin ^a   Mindikoglu, Ayse L ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Alpha 1 antitrypsin MZ phenotype; Drug induced liver injury; Green tea; Hepatotoxicity; SlimQuick

Indexed keywords

EID: 84876533957     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v4.i4.154     Document Type: Article

References (22)

1. Boehm K, Borrelli F, Ernst E, Habacher G, Hung SK, Milazzo S, Horneber M. Green tea (Camellia sinensis) for the prevention of cancer. Cochrane Database Syst Rev 2009; CD005004
2. Johnson IT. Green tea and cancer. Lancet Oncol 2010; 11: 519-520
3. Lambert JD, Elias RJ. The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention. Arch Biochem Biophys 2010; 501: 65-72
4. Schneider C, Segre T. Green tea: potential health benefits. Am Fam Physician 2009; 79: 591-594
5. Lambert JD, Kennett MJ, Sang S, Reuhl KR, Ju J, Yang CS. Hepatotoxicity of high oral dose (-)-epigallocatechin-3-gallate in mice. Food Chem Toxicol 2010; 48: 409-416
6. Fong TL, Klontz KC, Canas-Coto A, Casper SJ, Durazo FA, Davern TJ, Hayashi P, Lee WM, Seeff LB. Hepatotoxicity due to hydroxycut: a case series. Am J Gastroenterol 2010; 105: 1561-1566
7. Sarma DN, Barrett ML, Chavez ML, Gardiner P, Ko R, Mahady GB, Marles RJ, Pellicore LS, Giancaspro GI, Low Dog T. Safety of green tea extracts: a systematic review by the US Pharmacopeia. Drug Saf 2008; 31: 469-484
8. Mazzanti G, Menniti-Ippolito F, Moro PA, Cassetti F, Raschetti R, Santuccio C, Mastrangelo S. Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol 2009; 65: 331-341
9. Bjornsson E, Olsson R. Serious adverse liver reactions associated with herbal weight-loss supplements. J Hepatol 2007; 47: 295-297; author reply 297-298
10. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-1934
11. Ruchelli ED, Horn M, Taylor SR. Severe chemotherapy-related hepatic toxicity associated with MZ protease inhibitor phenotype. Am J Pediatr Hematol Oncol 1990; 12: 351-354
12. Natural Medicines Comprehensive Database. Available from URL: http://naturaldatabase.therapeuticresearch.com.proxy-hs.researchport.umd.edu/home.aspx?cs=SCHOOLNOPL~UMD&s=ND. Accessed on October 22, 2010
13. Nowak AK, Shilkin KB, Jeffrey GP. Darkroom hepatitis after exposure to hydroquinone. Lancet 1995; 345: 1187
14. Schindler G, Patzak U, Brinkhaus B, von Niecieck A, Wittig J, Krähmer N, Glöckl I, Veit M. Urinary excretion and metabolism of arbutin after oral administration of Arctostaphylos uvae ursi extract as film-coated tablets and aqueous solution in healthy humans. J Clin Pharmacol 2002; 42: 920-927
15. O'Donaghue JL, Richardson DP, Dyer WM. Hydroquinone and hepatitis. Lancet 1995; 346: 1427-1428
16. McGee J, Patrick RS, Wood CB, Blumgart LH. A case of veno-occlusive disease of the liver in Britain associated with herbal tea consumption. J Clin Pathol 1976; 29: 788-794
17. Graziadei IW, Joseph JJ, Wiesner RH, Therneau TM, Batts KP, Porayko MK. Increased risk of chronic liver failure in adults with heterozygous alpha1-antitrypsin deficiency. Hepatology 1998; 28: 1058-1063
18. Topic A, Alempijevic T, Milutinovic AS, Kovacevic N. Alpha-1-antitrypsin phenotypes in adult liver disease patients. Ups J Med Sci 2009; 114: 228-234
19. Hodges JR, Millward-Sadler GH, Barbatis C, Wright R. Heterozygous MZ alpha 1-antitrypsin deficiency in adults with chronic active hepatitis and cryptogenic cirrhosis. N Engl J Med 1981; 304: 557-560
20. Regev A, Guaqueta C, Molina EG, Conrad A, Mishra V, Brantly ML, Torres M, De Medina M, Tzakis AG, Schiff ER. Does the heterozygous state of alpha-1 antitrypsin deficiency have a role in chronic liver diseases? Interim results of a large case-control study. J Pediatr Gastroenterol Nutr 2006; 43 Suppl 1: S30-S35
21. Halangk J, Witt H, Puhl G, Gäbelein G, Pascu M, Müller T, Wiedenmann B, Neuhaus P, Berg T. Heterozygous alpha-1 antitrypsin deficiency as an inherited risk factor in the development of chronic liver disease. J Hepatol 2009; 50 Suppl 1: S162-S162
22. Rakela J, Goldschmiedt M, Ludwig J. Late manifestation of chronic liver disease in adults with alpha-1-antitrypsin deficiency. Dig Dis Sci 1987; 32: 1358-1362